Key result
Moderate-to-severe chemotherapy-induced anemia linked to ~248% higher odds of decreased quality of life in breast cancer.
Why the study?
Chemotherapy-induced anemia is frequent among breast cancer patients receiving systemic chemotherapy and is linked to fatigue and poor quality of life, but its prevalence and specific quality-of-life impact warranted evaluation.
Cross-Sectional (n=100)
No
Odds Ratio: 3.48 (95% CI 1.62–7.45)
p-value: p=0.001
Chemotherapy-induced anemia is highly prevalent in breast cancer patients and significantly impairs their quality of life.
No takes yet. Share an insight, caveat, or question.
Supports anemia monitoring in breast cancer chemotherapy; extends associations but leaves causal effects open for trials.
Batool et al. (2026) conducted a cross-sectional in breast cancer (n=100). Moderate-to-severe chemotherapy-induced anemia vs. Mild or no anemia was evaluated on decreased quality of life (OR 3.48, 95% CI 1.62-7.45, p=0.001). Moderate-to-severe chemotherapy-induced anemia independently predicted decreased quality of life in breast cancer patients (OR 3.48; 95% CI 1.62-7.45; P=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: